Bedlack, R. S. http://orcid.org/0000-0003-4666-7495
Cudkowicz, M. E.
Paganoni, S.
Khan-Tareen, H.
Andrews, J. A.
Article History
Accepted: 3 August 2021
First Online: 13 November 2021
Declarations
:
: Richard Bedlack: Dr. Bedlack has research funding from the ALS Association, Healey Center, Orion, and MediciNova. He serves as a consultant for AB Science, Alexion, ALSA, Amylyx, Biogen, Brainstorm Cell, Corcept, Cytokinetics, GenieUs, Guidepoint, ITF Pharma, Mallinkrodt, New Biotic, Orphazyme, Shinkei, and Woolsey Pharma.Merit Cudkowicz: Nothing to disclose.Hamza Khan-tareen: Nothing to disclose.Jinsy A. Andrews: Dr. Andrews serves as a consultant for AL-S pharma, Amylyx, Biogen, Cytokinetics, Denali, Orphazyme, and Wave Therapeutics. She receives research funding from Alexion, Biogen, Cytokinetics, Orion, MGH/Healey Center for ALS, and NIH/NeuroNEXT.